Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
复制标题
DOI：
10.14309/ajg.0000000000001157
复制
发表时间：
2021-06-01
影响因子：
9.8
通讯作者：
Toyoda, Hidenori
中科院分区：
文献类型：
--
作者：
Nguyen, Mindie H.;Atsukawa, Masanori;Toyoda, Hidenori
简介：恩替卡韦（ETV）和替诺福韦艾拉酚胺（TAF）都是一线治疗B型肝炎病毒（HBV）的药物，但从ETV转换为TAF的结果数据有限。我们的目的是评估ETV转换为TAF.METHODS后96周的结果：纳入了15个中心（美国、韩国、日本和台湾）的ETV治疗（>= 12个月）的慢性B型肝炎患者转换为TAF的常规实践。主要结果是完全病毒抑制（CVS）率（HBV DNA
INTRODUCTION: Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96 weeks after ETV-to-TAF switch.METHODS: ETV-treated (>= 12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included. Primary outcome was complete viral suppression (CVS) rate (HBV DNA